Abstract
Photoactivated chemotherapy (PACT) is a novel cancer treatment method that has drawn increasing attention due to its high selectivity and low side effects by spatio-temporal control of irradiation. Compared with photodynamic therapy (PDT), oxygen-independent PACT is more suitable for treating hypoxic tumors. By finely tuning ligand structures and coordination configurations, many Ru(II) complexes can undergo photoinduced ligand dissociation, and the resulting Ru(II) aqua species and/or free ligands may have anticancer activity, showing their potential as PACT agents. In this mini-review, we summarized the progress in Ru(II)-based PACT agents, as well as challenges that researchers in this field still face.
Highlights
The research of new chemotherapeutic drugs for cancer treatment has been the focus in medicine and related fields for many years
Many photoactivated Pt(IV) agents have been reported, which are nontoxic in the dark but can release cytotoxic Pt(II) species upon light irradiation [17,18]. These kinds of prodrugs are commonly known as photoactivated chemotherapy (PACT) agents, which can trigger and limit the drug activity within the tumor tissues by spatio-temporal control of irradiation, achieving fewer side effects [19,20,21]
Complexes, Ru(II)-based Photoactivated chemotherapy (PACT) agents have some promising advantages. They possess diverse and easy-modified structures, rich photophysical and photochemical properties, and the octahedral structures different from that of cisplatin may endow them with good activity against cisplatin-resistant cancer cells [42,43,44]
Summary
The research of new chemotherapeutic drugs for cancer treatment has been the focus in medicine and related fields for many years. Many photoactivated Pt(IV) agents have been reported, which are nontoxic in the dark but can release cytotoxic Pt(II) species upon light irradiation [17,18] These kinds of prodrugs are commonly known as photoactivated chemotherapy (PACT) agents, which can trigger and limit the drug activity within the tumor tissues by spatio-temporal control of irradiation, achieving fewer side effects [19,20,21]. Complexes, Ru(II)-based PACT agents have some promising advantages They possess diverse and easy-modified structures, rich photophysical and photochemical properties, and the octahedral structures different from that of cisplatin may endow them with good activity against cisplatin-resistant cancer cells [42,43,44]. DNA-binding ability, showing potential in photoactivated chemotherapy This mini-review aims to present the latest progress in photoinduced ligand dissociation related Ru(II)-based. The research on ligand dissociation efficiency is the focus of developing potential Ru(II)-based PACT drugs
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
